This HTML5 document contains 146 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n9http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37117099
rdf:type
wikibase:Item
schema:description
vědecký článek vedecký článok article científic مقالة علمية نشرت في 27 أكتوبر 2008 articolo scientifico artigo científico article scientifique videnskabelig artikel wetenschappelijk artikel наукова стаття, опублікована в жовтні 2008 scientific article published on 27 October 2008 vetenskaplig artikel научни чланак bilimsel makale wissenschaftlicher Artikel artículu científicu espublizáu en 2008
p:P577
wds:Q37117099-2F06C3D9-8459-44A8-B193-844E865D33C6
wdt:P577
2008-10-27T00:00:00Z
p:P407
wds:Q37117099-A6C72A75-5BF5-4232-B092-0637DE76B97A
wdt:P407
wd:Q1860
p:P2860
wds:Q37117099-4106D481-AF92-41D8-8A93-1D261F4842CE wds:Q37117099-46762080-3C8E-45AE-869B-FD11E2F38B79 wds:Q37117099-51C6822E-075A-4984-ADA6-CFCB2FEC7A61 wds:Q37117099-533875D0-B0E4-48C8-AAD3-FFB7DCE73A97 wds:Q37117099-55334534-32F1-4A03-B736-9E7F0D983A31 wds:Q37117099-5766FE2C-353C-43FE-A143-F229CD3B3A32 wds:Q37117099-6B659862-DA75-41DE-883E-A748450F000D wds:Q37117099-89166877-99CA-42DC-872F-11000E7EEFD7 wds:Q37117099-892B5DB7-2934-4694-91A0-7BB3C4B28C62 wds:Q37117099-9CEF590D-5FFF-4BCA-B27F-CC37A35F4D78 wds:Q37117099-9F795FB2-BE13-4A60-B7D8-04D1948B74F9 wds:Q37117099-AA9712BE-CD08-4A6A-AA0B-E8FE362DDC08 wds:Q37117099-AAD87005-90D4-4F06-93EB-F84325CABA40 wds:Q37117099-AFC73064-782B-4B76-BFAF-B0D701FA2250 wds:Q37117099-B64A939B-53E7-4696-B38C-F968C14EF5E3 wds:Q37117099-BD3E6D63-EB14-4DF7-B279-5909DDAD0BE8 wds:Q37117099-BF742C1D-8CF5-4661-AC32-0D3493041418 wds:Q37117099-C0630700-1BD4-4164-B406-3C893A02D236 wds:Q37117099-D8A11A9C-4422-4FDF-B9B6-429455F6C042 wds:Q37117099-DAF266E2-8772-470E-93C8-CAB9B0DA54D2 wds:Q37117099-F434F662-A225-451C-8298-086334E4636A wds:Q37117099-F73944B7-1A81-43EA-92A1-0B185236BE78 wds:Q37117099-05EF27CB-D84C-4FD7-84B4-2EF2A7999413 wds:Q37117099-0F0878EB-D01A-4144-B073-3EC184F16C82 wds:Q37117099-15555AE7-6E42-489D-B34F-8F767A10855A wds:Q37117099-2F8B39CE-285B-4B10-B351-A14F73E56024 wds:Q37117099-31131A54-6DC4-4F78-AB8F-5ACEBAC4E043 wds:Q37117099-391C0C95-E417-42F6-A3BA-9BCA052D6365
wdt:P2860
wd:Q43797374 wd:Q29618610 wd:Q44374942 wd:Q40866333 wd:Q27824868 wd:Q28118852 wd:Q45151889 wd:Q27824798 wd:Q28272917 wd:Q35809846 wd:Q55246254 wd:Q44850183 wd:Q34551403 wd:Q46658501 wd:Q40783216 wd:Q44075449 wd:Q27824804 wd:Q34099051 wd:Q34743609 wd:Q35886298 wd:Q34553656 wd:Q27824837 wd:Q33941495 wd:Q34169772 wd:Q46687838 wd:Q44956779 wd:Q34587751 wd:Q34546186
p:P2093
wds:Q37117099-256D8153-8B04-4DA9-9CE8-2F4A53329859 wds:Q37117099-19D6EED8-9B4E-448C-8F78-A08AD181202C wds:Q37117099-E9CA38EC-374C-4997-99B0-5EB913283240 wds:Q37117099-EAB10475-712D-4B3D-BB04-8E536F62B1E4 wds:Q37117099-9B24B97B-6ADB-4439-9EB9-D39FE331779B wds:Q37117099-90F65F98-6EA1-4FC8-B298-0516CDDA53DA wds:Q37117099-7616C855-5AAC-4EDC-8749-7FEEE536D919 wds:Q37117099-AAC24E63-B9DE-4BFC-8AD5-B36DBC6EF364 wds:Q37117099-3C4F6873-3716-406B-AAFA-6AE97F69934B wds:Q37117099-75596191-7C56-4FD2-BA64-7D665811700E wds:Q37117099-623D4635-8AB0-4842-8E22-E5641E3791C8
wdt:P2093
Charles D Blanke Vivien H Bramwell Kouros Owzar Christopher D M Fletcher Cathryn Rankin Donna Hollis Christopher W Ryan Ernest C Borden Jonathan A Fletcher Robert S Benjamin Christopher L Corless
rdfs:label
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol
skos:prefLabel
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol
schema:name
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol
p:P50
wds:Q37117099-567409C5-FBD6-4245-837F-7BE7596B7422 wds:Q37117099-3D234A64-D15A-485C-BD65-E44009312F57 wds:Q37117099-C63F6338-F8CF-4DBE-AC8E-57F54A0DF535 wds:Q37117099-139EA8BC-5F1E-498A-804F-97A1B4304062
wdt:P50
wd:Q91718593 wd:Q66809438 wd:Q96229532 wd:Q40526741
p:P1476
wds:Q37117099-0DB8CFC9-4EA6-401E-BBCF-72B6D9E8EB05
wdt:P1476
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol
p:P304
wds:Q37117099-9C222265-EF2B-4AEF-BE85-2A38532A010C
wdt:P304
5360-5367
p:P31
wds:Q37117099-F72C139F-C4B5-4C88-9113-85CABE5E0E86
wdt:P31
wd:Q13442814
p:P921
wds:Q37117099-7C2B343D-7062-435A-95EB-B1D7373AE467 wds:Q37117099-86345C5A-9E13-49BF-A874-8A57C43FC2CD wds:Q37117099-0DEFBBF3-B6C6-48CE-A637-6992F6D9B5A7 wds:Q37117099-C01911C5-C7F8-4BB1-8B45-DF255DD491A0
wdt:P921
wd:Q1495661 wd:Q177094 wd:Q29496 wd:Q42824827
p:P698
wds:Q37117099-C531D1D7-E2D7-4733-B612-6A397F28D318
wdtn:P698
n12:18955451
wdt:P698
18955451
p:P1433
wds:Q37117099-398FCF7B-67BD-4754-BFEB-A290302E6F79
wdt:P1433
wd:Q400292
p:P433
wds:Q37117099-42FDF66D-5BE1-4774-BF51-9642F5749FFE
p:P478
wds:Q37117099-0C7A58A6-6545-41B0-83DC-A4C4B9D57B00
wdt:P433
33
wdt:P478
26
p:P356
wds:Q37117099-67ED1462-BA94-40A9-ACB6-B35735E0F210
wdtn:P356
n9:JCO.2008.17.4284
wdt:P356
10.1200/JCO.2008.17.4284
p:P5875
wds:Q37117099-5AA712A7-5B74-4D0E-B458-2639224A661D
wdt:P5875
23423231
p:P932
wds:Q37117099-38B2AA13-1D8D-466E-BC75-89DDE542FE79
wdt:P932
2651078